Kimio Yonesaka

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +17

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 670 citations

Medicine, Oncology, Pharmacology +17

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Koji Haratani, Hidetoshi Hayashi, Taro Tanaka et al. · Annals of Oncology · 2017 · 294 citations · Full text

Medicine, Immunology, Oncology +17

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Dalia Ercan, Kreshnik Zejnullahu, Kimio Yonesaka et al. · Oncogene · 2010 · 227 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +13

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi et al. · Journal of Thoracic Oncology · 2017 · 227 citations

Medicine, Oncology, Pharmacology +14